Evidence map›Paper›PMID 32583039›Full record

ReviewWorld journal of urology2021

Role of multiparametric prostate MRI in the management of prostate cancer.

Luke P O'Connor, Amir H Lebastchi, Rahim Horuz, Ardeshir R Rastinehad, M Minhaj Siddiqui, Jeremy Grummet, Christof Kastner, Hashim U Ahmed, Peter A Pinto, Baris Turkbey

Abstract readReview
PubMed Publisher
In one paragraph

Review in World journal of urology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Surveillance after Focal Therapy - a Comprehensive Review.Prostate cancer and prostatic diseases · 2025
    Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Luke P O'Connor *Urologic Oncology Branch, National Cancer Institute, NIH, Bethesda, MD, USA.
Amir H Lebastchi *Urologic Oncology Branch, National Cancer Institute, NIH, Bethesda, MD, USA.
Rahim HoruzDepartment of Urology, Istanbul Medipol University, Istanbul, Turkey.
Ardeshir R RastinehadDepartment of Urology, Lenox Hill Hospital Northwell Health, New York, NY, USA.
M Minhaj SiddiquiDivision of Urology, University of Maryland School of Medicine, Baltimore, MD, USA.
Jeremy GrummetDepartment of Surgery, Central Clinical School, Monash University, Melbourne, VIC, Australia.
Christof KastnerDepartment of Urology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Hashim U AhmedImperial Prostate, Division of Surgery, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK.
Peter A PintoUrologic Oncology Branch, National Cancer Institute, NIH, Bethesda, MD, USA.
Baris TurkbeyMolecular Imaging Program, National Cancer Institute, NIH, 10 Center Drive Room B3B85, Bethesda, MD, USA. turkbeyi@mail.nih.gov.

Funding

Imaging, image guided biopsy and treatment of prostate cancerZIABC012062 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI TÜRKBEY, BARIS · 2021 to 2025
$1.3M
Wellcome Trust 204998/Z/16/Z
6 · The paper itself

Abstract

introductionProstate cancer has traditionally been diagnosed by an elevation in PSA or abnormal exam leading to a systematic transrectal ultrasound (TRUS)-guided biopsy. This diagnostic pathway underdiagnoses clinically significant disease while over diagnosing clinically insignificant disease. In this review, we aim to provide an overview of the recent literature regarding the role of multiparametric MRI (mpMRI) in the management of prostate cancer. MATERIALS AND

methodsA thorough literature review was performed using PubMed to identify articles discussing use of mpMRI of the prostate in management of prostate cancer.

conclusionThe incorporation of mpMRI of the prostate addresses the shortcomings of the prostate biopsy while providing several other advantages. mpMRI allows some men to avoid an immediate biopsy and permits visualization of areas likely to harbor clinically significant cancer prior to biopsy to facilitate use of MR-targeted prostate biopsies. This allows for reduction in diagnosis of clinically insignificant disease as well as improved detection and better characterization of higher risk cancers, as well as the improved selection of patients for active surveillance. In addition, mpMRI can be used for selection and monitoring of patients for active surveillance and treatment planning during surgery and focal therapy.

Indexed as

Multiparametric Magnetic Resonance ImagingHumansMaleProstatic NeoplasmsActive surveillanceFusion biopsyMultiparametric MRI (mpMRI)Prostate cancerProstatectomy

Identifiers

PMID32583039

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.